# Nephroprotective effects of visnagin through modulation of macrophage polarization, oxidative stress, inflammation and apoptosis in renal I/R injury

**Authors:** Suleyman Sagir, Ugur Seker, Merve Pekince-Ozoner, Meral Yuksel, Gul Sahika Gokdemir, Seval Kaya, Mehmet Demir

PMC · DOI: 10.1515/med-2026-1399 · 2026-03-09

## TL;DR

Visnagin protects the kidneys from injury by reducing inflammation, oxidative stress, and harmful immune responses in a rat model.

## Contribution

This study demonstrates visnagin's ability to modulate macrophage polarization and reduce renal ischemia-reperfusion injury in rats.

## Key findings

- Visnagin at 60 mg/kg reduced oxidative stress markers like MDA and increased GSH in renal tissue.
- Treatment decreased pro-inflammatory cytokines IL-1β and IL-6 and modulated M1/M2 macrophage polarization.
- Visnagin lowered apoptotic markers Bax and caspase-3 and improved histopathological outcomes.

## Abstract

The study aimed to investigate the nephroprotective effects of visnagin on renal ischemia-reperfusion (I/R) injury and the role of M1/M2 macrophage polarization in this process.

Forty-two adult rats were divided into six groups: Control, Visnagin30 mg/kg, Visnagin60 mg/kg, I/R, I/R + Visnagin30 mg/kg, I/R + Visnagin60 mg/kg (n=7). Bilateral renal ischemia was induced by clamping for 25 min, followed by 2 h of reperfusion. Visnagin or vehicle was administered to the animals intraperitoneally 2 h before reperfusion. At the end of the study, kidney samples were collected for analysis of oxidative stress, inflammatory cytokines, apoptotic protein expression, and M1/M2 macrophage polarization.

I/R injury increased malondialdehyde (MDA), chemiluminescence (CL), IL-1β, and IL-6 levels while decreasing glutathione (GSH) in renal tissue, indicating enhanced oxidative stress (p<0.001) and inflammation (p<0.05). Histopathological examination showed glomerular atrophy, tubular degeneration, and intertubular hemorrhage. Visnagin treatment at 60 mg/kg significantly reduced MDA, CL, and IL-1β levels, and increased GSH (p<0.05). Immunohistochemically, visnagin decreased Bax (p<0.001), caspase-3 (p<0.01), and TNF-α (p<0.01) expressions elevated by I/R injury. Furthermore, visnagin reversed I/R induced M1/M2 macrophage polarization (CD86↑, CD163↓), decreasing CD86 (p<0.05) and increasing CD163 immunodensity (p<0.05).

Visnagin treatment (60 mg/kg) exerts promising nephroprotective effects in renal I/R injury by reducing oxidative stress, inflammation, apoptosis, and modulating M1/M2 macrophage polarization.

## Linked entities

- **Proteins:** BAX (BCL2 associated X, apoptosis regulator), Casp3 (caspase 3), TNF (tumor necrosis factor), CD86 (CD86 molecule), CD163 (CD163 molecule)
- **Chemicals:** visnagin (PubChem CID 6716), glutathione (GSH) (PubChem CID 124886), IL-6 (PubChem CID 165368475)
- **Species:** Rattus norvegicus (taxon 10116)

## Full-text entities

- **Genes:** SOD1 (superoxide dismutase 1) [NCBI Gene 6647] {aka ALS, ALS1, HEL-S-44, IPOA, SOD, STAHP}, CAT (catalase) [NCBI Gene 847], Cd86 (CD86 molecule) [NCBI Gene 56822] {aka B7-2}, Akt1 (AKT serine/threonine kinase 1) [NCBI Gene 24185] {aka Akt}, Jak2 (Janus kinase 2) [NCBI Gene 24514], IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, Casp3 (caspase 3) [NCBI Gene 25402] {aka CPP32-beta, Lice, Yama}, Bcl2 (BCL2, apoptosis regulator) [NCBI Gene 24224] {aka Bcl-2}, Ptgs2 (prostaglandin-endoperoxide synthase 2) [NCBI Gene 29527] {aka COX-2, Cox2, PGHS-2, PHS II, Pghs2}, Pik3cg (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma) [NCBI Gene 298947] {aka Pi3k}, Ifng (interferon gamma) [NCBI Gene 25712] {aka IFNG2, If2f}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, Stat3 (signal transducer and activator of transcription 3) [NCBI Gene 25125], Il1b (interleukin 1 beta) [NCBI Gene 24494] {aka IL-1F2}, Mir10a (microRNA 10a) [NCBI Gene 100313996] {aka rno-mir-10a}, Tnf (tumor necrosis factor) [NCBI Gene 24835] {aka RATTNF, TNF-alpha, Tnfa}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, BAX (BCL2 associated X, apoptosis regulator) [NCBI Gene 581] {aka BCL2L4}, Il4 (interleukin 4) [NCBI Gene 287287] {aka Il4e12}, Il6 (interleukin 6) [NCBI Gene 24498] {aka ILg6, Ifnb2}, Bax (BCL2 associated X, apoptosis regulator) [NCBI Gene 24887], Il13 (interleukin 13) [NCBI Gene 116553], Mtor (mechanistic target of rapamycin kinase) [NCBI Gene 56718] {aka Frap1, RAFT1}, Il10 (interleukin 10) [NCBI Gene 25325] {aka IL10X, If2a}, Cd163 (CD163 molecule) [NCBI Gene 312701] {aka ED2}, Tgfb1 (transforming growth factor, beta 1) [NCBI Gene 59086] {aka Tgfb}, CASP3 (caspase 3) [NCBI Gene 836] {aka CPP32, CPP32B, SCA-1}
- **Diseases:** kidney stone (MESH:D007669), hydronephrosis (MESH:D006869), renal artery stenosis (MESH:D012078), /R (MESH:C580424), ischemic brain injury (MESH:D001930), I/R (MESH:D015427), tissue damage (MESH:D017695), sepsis (MESH:D018805), cardiac damage and dysfunction (MESH:D006331), renal colic (MESH:D056844), injured kidney (MESH:D007674), atrophy (MESH:D001284), edema (MESH:D004487), chronic kidney injury (MESH:D051436), cerebral ischemia (MESH:D002545), pain (MESH:D010146), inflammation (MESH:D007249), trauma (MESH:D014947), cerebral ischemic (MESH:D002547), hypoxia (MESH:D000860), renal ischemic (MESH:D006030), hypotension (MESH:D007022), Renal ischemia (MESH:D007511), myocardial injury (MESH:D009202), acute kidney dysfunction (MESH:D058186), hemorrhage (MESH:D006470)
- **Chemicals:** MDA (MESH:D008315), Hematoxylin (MESH:D006416), lucigenin (MESH:C033472), naringin (MESH:C005274), H2O2 (MESH:D006861), A. visnaga seed extract (-), superoxide (MESH:D013481), NO (MESH:D009614), trimetazidine (MESH:D014292), DMSO (MESH:D004121), creatinine (MESH:D003404), formalin (MESH:D005557), ROS (MESH:D017382), luteolin (MESH:D047311), PBS (MESH:D007854), eosin (MESH:D004801), DAB (MESH:C000469), thiobarbituric acid- reactive substances (MESH:D017392), alcohol (MESH:D000438), lipid (MESH:D008055), LPS (MESH:D008070), isoproterenol (MESH:D007545), Luminol (MESH:D008165), citrate (MESH:D019343), GSH (MESH:D005978), CCl4 (MESH:D002251), hypochlorous acid (MESH:D006997), xylene (MESH:D014992), oxalate (MESH:D010070), xylazine (MESH:D014991), flavone (MESH:C043562), oxygen (MESH:D010100), paraffin (MESH:D010232), nitric oxides (MESH:D009569), Visnagin (MESH:C044999), hydroxyl radicals (MESH:D017665), prostaglandin E2 (MESH:D015232), water (MESH:D014867)
- **Species:** Homo sapiens (human, species) [taxon 9606], Rattus norvegicus (brown rat, species) [taxon 10116]

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12965831/full.md

---
Source: https://tomesphere.com/paper/PMC12965831